Fitterfly Diabetes Digital Therapeutics Program Improves Blood Sugar Levels & Promotes Weight Loss In People With Type 2 Diabetes

The Fitterfly Diabetes continuous glucose monitoring (CGM) digital therapeutic program for managing glycemic control and weight in people with type 2 diabetes helped 85% reduce their hemoglobin A1c (HbA1c) levels by 1.2%. The reduction was even higher, at about 2.6%, for those participants who started the program with an HbA1c level greater than 9%. The program is designed to provide individuals with the tools they need to manage their condition effectively and make long-term lifestyle changes that would support their overall health.

The reduction in HbA1c was noted a study using de-identified data of 109 participants . . .